No. Retatrutide is not FDA approved as of September 2026. It is an investigational drug in Phase 3 trials, and Eli Lilly has signalled plans to file for approval in the first quarter of 2027. With a typical 10 to 12 month FDA review, a realistic approval window is late 2027 into 2028. Any Miami clinic offering retatrutide today is not dispensing an approved medication, and that distinction matters more than the trial results do.
We are writing this because we get asked about retatrutide constantly at our Brickell clinic, and because the search results people arrive with are not always careful about the difference between promising in trials and available by prescription. Here is the accurate picture, what the data actually shows, and what is legitimately available to you in Miami right now.
Retatrutide is a triple agonist. Where semaglutide acts on one receptor pathway (GLP-1) and tirzepatide acts on two (GLP-1 and GIP), retatrutide acts on three: GLP-1, GIP and glucagon. The addition of glucagon receptor activity is the mechanistic reason it has attracted so much attention, because it is thought to contribute to energy expenditure rather than appetite suppression alone.
That is a meaningful pharmacological step, and it is why the drug is being studied seriously rather than hyped into existence. It is also not the same thing as being available, and the gap between those two states is where most of the confusion in this category lives.
The Phase 3 programme, run under the TRIUMPH name, has reported results across several patient populations. The headline figures are genuinely large.
| Trial | Population | Average weight loss at 80 weeks |
|---|---|---|
| TRIUMPH-1 | Obesity | Up to 28.3 percent of body weight at the 12 mg dose |
| TRIUMPH-2 | Obesity with type 2 diabetes | Up to 20.8 percent |
| TRIUMPH-3 | Severe obesity with cardiovascular disease | Up to 22.6 percent |
For context, that upper figure sits above what tirzepatide and semaglutide have reported in their own trials, which is why retatrutide is routinely described as a next-generation agent. It is a fair description of the data.
Two caveats belong next to those numbers. First, trial averages at a maximum tolerated dose are not what an average patient experiences in ordinary clinical practice, where adherence, dose tolerance and follow-up all vary. Second, Phase 3 results are a snapshot on the way to a regulatory decision, not the decision itself. The FDA reviews safety data in far more detail than a press release conveys.
An investigational drug has no approved manufacturer supply outside of clinical trials. That single fact determines everything about what you might be offered.
If a clinic, telehealth service or online vendor is selling you retatrutide in Miami in 2026, the material is not coming from an approved commercial supply, because none exists. It is coming from a research chemical supplier, typically labelled research use only. That label is not a technicality. It exists specifically so vials can be sold outside the pharmacy system, without the identity, purity and sterility testing a licensed compounding pharmacy performs.
It also means there is no established clinical dosing guidance to follow, no approved prescribing information, and no adverse event reporting infrastructure behind what you are injecting. You cannot verify the concentration, the purity or in many cases the identity of the compound. For a drug with real pharmacological activity across three receptor pathways, that is not a small unknown.
We do not prescribe retatrutide at Nexsis BioHealth, and we will not until there is an approved product a licensed pharmacy can fill. This is the same standard we apply across peptide therapy generally, and it is the reason we can tell you which licensed pharmacy fills every prescription we write.
The good news for anyone drawn to retatrutide by the trial numbers is that approved medications in the same class are available today, with substantial evidence behind them and a real supply chain.
Tirzepatide is a dual GLP-1 and GIP agonist, FDA approved in its obesity-labeled form for chronic weight management. In its own Phase 3 programme it produced weight loss in the low-to-mid twenties percent range at higher doses. It is the closest approved analogue to what retatrutide promises.
Semaglutide is a GLP-1 agonist, FDA approved for chronic weight management in its obesity-labeled form, with the largest real-world evidence base in the category and well-characterised cardiovascular outcome data.
Both are available through licensed pharmacies, and both are now sold direct to self-pay patients by their manufacturers at roughly $200 to $450 per month depending on dose and programme tier. Those prices move frequently, so confirm current figures before you budget.
Our Medical Weight Loss program in Brickell is built around these approved agents. It runs six months at $1,800 and includes the physician consultation, lab review, GLP-1 medication management, InBody body composition tracking and ongoing clinical support. The reason we track body composition rather than scale weight is directly relevant here: aggressive weight loss on any of these drugs costs lean mass as well as fat, and the only way to know which you are losing is to measure it.
There is a legitimate route, and it is the clinical trial system. The Phase 3 programme has run across multiple sites and indications, and trial participation is the only way to receive pharmaceutical-grade retatrutide with proper monitoring at no drug cost to you. Enrolment criteria are specific and sites open and close, so the search has to be done in real time rather than from a blog post.
If the drug is approved on the timeline that has been signalled, it becomes prescribable in late 2027 or 2028. Patients who start an approved GLP-1 protocol now are not locked out of that. Switching agents when a better-suited one becomes available is a normal clinical decision, and starting supervised treatment today is strictly better than waiting two years for a molecule that may or may not arrive on schedule.
Our clinical team, led by Dr. Alvaro J. Ocampo, Pathologist and Environmental Medicine Physician, sorts every compound a patient asks about into one of three categories: FDA approved for your indication, approved for something else and prescribed off-label, or not approved at all. All three are legitimate categories to discuss. Only the third is a category we decline to prescribe from, and retatrutide currently sits there.
We see patients across Miami, from Brickell and Coral Gables to Coconut Grove, Downtown and Key Biscayne, and the retatrutide question comes up regularly in metabolic consultations. We would rather answer it properly than let someone buy an unregulated vial because we were vague.
Book a consultation with our Brickell physician team and we will review your labs, your history and your goals, and tell you which approved option fits, or whether medication is the right route for you at all.
No. Retatrutide remains an investigational drug in Phase 3 trials as of September 2026. Eli Lilly has indicated it plans to submit for approval in the first quarter of 2027, and with a standard 10 to 12 month review, approval would realistically fall in late 2027 or 2028 if granted.
Not legitimately. There is no approved commercial supply, so anything sold as retatrutide today comes from research chemical suppliers operating outside the pharmacy system, with no identity, purity or sterility testing. Nexsis BioHealth does not prescribe it and will not until an approved product exists.
The TRIUMPH-1 trial reported average weight loss of up to 28.3 percent of body weight at 80 weeks on the 12 mg dose. Trials in patients with type 2 diabetes and with severe obesity plus cardiovascular disease reported up to 20.8 percent and 22.6 percent respectively. These are trial averages at maximum tolerated doses, not typical real-world outcomes.
Retatrutide acts on three receptor pathways (GLP-1, GIP and glucagon) against tirzepatide two and semaglutide one, and its trial weight loss figures are correspondingly higher. The decisive difference for a patient today is that tirzepatide and semaglutide are FDA approved and available through licensed pharmacies, and retatrutide is not.
For most patients, no. Approval is at least a year away and not guaranteed, while approved agents with strong evidence are available today. Switching to a newer agent later is a routine clinical decision, so starting supervised treatment now does not close that door.
That label exists so vials can be sold outside the pharmacy system, skipping the testing a licensed compounding pharmacy performs. You have no reliable way to verify what is in the vial or at what concentration. Sourcing is the single largest safety variable in this entire category.
